These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic targets in idiopathic pulmonary fibrosis. Kolb M; Bonella F; Wollin L Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042 [TBL] [Abstract][Full Text] [Related]
4. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914 [TBL] [Abstract][Full Text] [Related]
6. Update in diffuse parenchymal lung disease, 2013. Rosas IO; Kaminski N Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490 [TBL] [Abstract][Full Text] [Related]
7. Current approaches to the management of idiopathic pulmonary fibrosis. Raghu G; Richeldi L Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832 [TBL] [Abstract][Full Text] [Related]
8. Idiopathic pulmonary fibrosis: the turning point is now! Funke M; Geiser T Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356 [TBL] [Abstract][Full Text] [Related]
9. New treatments in idiopathic pulmonary fibrosis. Strâmbu I Pneumologia; 2016; 65(3):127-32. PubMed ID: 29542881 [TBL] [Abstract][Full Text] [Related]
11. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Raghu G Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment. Martinez FJ; Flaherty KR Chest; 2017 May; 151(5):1173-1174. PubMed ID: 28483105 [TBL] [Abstract][Full Text] [Related]
13. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. George PM; Wells AU Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906 [TBL] [Abstract][Full Text] [Related]
14. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Raghu G; Selman M Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489 [No Abstract] [Full Text] [Related]
16. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557 [TBL] [Abstract][Full Text] [Related]
17. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Hagmeyer L; Treml M; Priegnitz C; Randerath WJ Respiration; 2016; 91(4):327-32. PubMed ID: 27073887 [TBL] [Abstract][Full Text] [Related]
18. Update in Interstitial Lung Disease 2014. Belloli EA; Martinez FJ; Flaherty KR Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676 [No Abstract] [Full Text] [Related]